National Registry of Patients Diagnosed With Low-risk Myelodysplastic Syndromes According to the Criteria of the WHO / French-American-British Classification System (FAB) and IPSS and Treated With Erythropoietic Agents.
Review of RESMD data base in the group of patients with MDS from diagnosis of low risk
myelodysplastic syndrome (MDS) and occurrence of anemia that began treatment with
erythropoiesis stimulating agent (ESAs) / support transfusional before December 31, 2011. In
all cases, data obtained will be prior to the date of the start of the study to ensure its
retrospective nature, thus reflecting the routine use of erythropoietic agents in clinical
and non-interference in the doctor's clinical practice.
Observational Model: Case Control, Time Perspective: Retrospective
Collect and evaluate the Spanish experience of anemia treatment.
Collect and evaluate retrospectively the Spanish experience of anemia treatment in patients diagnosed with low-risk MDS according to IPSS (low or intermediate-1) evaluating the efficacy and safety of treatment with ESAs received for at least 24 weeks and the evolution of a control group of patients who received only transfusional support.
Maria Consuelo Cañizo, MD
Hospital Universitario de Salamanca
Spain: Spanish Agency of Medicines